Morel Yannis
@MorelYannis
Followers
20
Following
99
Media
0
Statuses
85
#AACR19 “#InnateImmunity & complement in #SolidTumors” Chair @EricVivier1 @InnatePharma's CSO @aphm_actu @univamu @Immunopole
0
7
11
Brilliant talk by @EricVivier1 @InnatePharma describing Innate's portfolio of biologics aimed at modulating of NK cell and CD8 T cell functions in TME. Very exciting to see unpublished data on bi-specific engagers as well as on adenosine pathway.
#AACR19 @EricVivier1 @InnatePharma’CSO @aphm_actu @univamu @Immunopole A novel multifunctional #antibodytechnology with a potential improved benefit-risk profil: bispecific #NKcellengagers (simultaneous binding of #CD16 & #NKp46 on #NKcells)
0
9
27
Our friend, #AlessandroMoretta (1953–2018): cofounder of @InnatePharma, Professor at @UniGenova, major figure of #CancerImmunology, one of the founding fathers of #NKimmunotherapy with @EricVivier1 See @NatImmunol
https://t.co/hyn2kNrM4z
@ImmunityCP
https://t.co/cA5GytjLgT
0
9
20
#AACR19 @EricVivier1 @InnatePharma: the #CD39-blocking antibody (IPH5201) promotes #antitumorimmunity across a wide range of tumors by preventing the production of #adenosine & promoting the accumulation of ATP in the #TumorMicroEnvironment More info https://t.co/YEBiwHL3Jb
0
7
9
#AACR19 “#InnateImmunity & complement in #SolidTumors” Chair @EricVivier1 @InnatePharma @aphm_actu @univamu @Immunopole @mellmani @genentech #RubénPío @CIMA_unav… packed room!
0
7
10
Beautiful talk by @MiriamMerad! @AACR describing phenotypic and functional diversity across DC subsets within the TME
0
6
36
ICYMI, @sloan_kettering scientists have identified new structures that play a critical role in one of the most protective kinds of #intercellular communication – the “lethal” interaction between a cytotoxic #Tcell and its targets: https://t.co/bSxUshQQha
0
29
64
Very proud of grad student, Dan Fu Ruan @df_ruan1 for stellar job in presenting effects of HLA-E expression as a major determinant of antitumor function at @KeystoneSymp . Thanks very much for the opportunity to present @Dr_Nick_Bikes @EricVivier1 #CarolineRobert an #LewisLanier!
0
5
32
study provides mechanistic insight on the role of KRAS in colorectal cancer resistance to immune-checkpoint inh https://t.co/Q9ImztF918
#colorectalcancer
cell.com
Liao et al. show that oncogenic KRAS represses IRF2 expression leading to high expression of CXCL3, which binds CXCR2 on MDSCs to promote their migration into the tumor microenvironment. Enforced...
1
26
54
Long lines of questions for the NK cell talks at @KeystoneSymp Lewis Lanier, Alberto Mantovani & myself we’re inundated by Q’s on how to drug the NK cell response to cancer. Amazing time to be a cancer immunology researcher
3
7
40
Targeting Innate Immunity in Cancer AACR 2019, Atlanta, March 31st https://t.co/ARzZLWdQ0x
#AACR19
2
3
10
Ce soir @InnatePharma est fière de recevoir le prix d’honneur 2019 des #Trophées de l'#Innovation d’@univamu avec @SATTse_ et @AMFrenchTech
1
12
17
#Trophées de l'#Innovation 2019 d’@univamu avec @SATTse_ @AMFrenchTech, @marseille @Immunopole à l’honneur : @InnatePharma reçoit le prix d’honneur tandis que @stephaniecornen remet le prix de la start-up santé à @ImcheckThx
0
6
13
1
6
10
Innate Pharma celebrates its 20th Anniversary and wishes you a happy new year 2019 ! #HappyNewYear
1
6
22
A #cytostatic drug combination induces #cancer cell #senescence while also triggering #NKcell-dependent #AntitumorImmunity. #Ruscetti et al @sciencemag
https://t.co/XxA7VBI5oM
0
4
3
In an analysis of KEYNOTE-028, T-cell–inflamed gene-expression profile, PD-L1 expression, and TMB were found to predict efficacy of pembrolizumab across 20 cancer types: https://t.co/YDgg5q9BYM
#ImmunoOnc
0
25
37
Induction of #senescence: one way for #chemotherapy & #immunity to join forces against #cancer, #NKcells in the spotlight. Perspective @sciencemag on #Ruscetti et al paper by @EricVivier1 & @stephaniecornen @InnatePharma @univamu @aphm_actu @Immunopole
https://t.co/TPYpjeH3AK
1
17
21